Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.

@article{Min2006CutaneousLV,
  title={Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.},
  author={Chang-Ki Min and Seok Jong Lee and Yoo-Jin Kim and Ki-Seong Eom and Jong-Wook Lee and W S Min and C C Kim and C Cho and Gyeong-sin Park},
  journal={European journal of haematology},
  year={2006},
  volume={76 3},
  pages={265-8}
}
The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-kappaB (NFkappaB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-alpha, and C-reactive protein (CRP). Bortezomib administration may… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Ixazomib-induced cutaneous necrotizing vasculitis

Supportive Care in Cancer • 2018
View 6 Excerpts
Highly Influenced

Bortezomib-induced inflammatory neuropathy.

Journal of the peripheral nervous system : JPNS • 2010
View 2 Excerpts

Similar Papers

Loading similar papers…